Switch theme
Sign up to access all valuation multiples
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.
2016
177
LTM Revenue $862M
LTM EBITDA $662M
$686M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HBM Holdings has a last 12-month revenue (LTM) of $862M and a last 12-month EBITDA of $662M.
In the most recent fiscal year, HBM Holdings achieved revenue of $4.9M and an EBITDA of $1.3M.
HBM Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HBM Holdings valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $862M | XXX | $4.9M | XXX | XXX | XXX |
| Gross Profit | $824M | XXX | $4.3M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $662M | XXX | $1.3M | XXX | XXX | XXX |
| EBITDA Margin | 77% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $436M | XXX | -$0.3M | XXX | XXX | XXX |
| EBIT Margin | 51% | XXX | -6% | XXX | XXX | XXX |
| Net Profit | $440M | XXX | $0.4M | XXX | XXX | XXX |
| Net Margin | 51% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, HBM Holdings's stock price is HKD 8 (or $1).
HBM Holdings has current market cap of HKD 6.2B (or $791M), and EV of HKD 5.4B (or $686M).
See HBM Holdings trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $686M | $791M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, HBM Holdings has market cap of $791M and EV of $686M.
HBM Holdings's trades at 141.3x EV/Revenue multiple, and 531.4x EV/EBITDA.
Equity research analysts estimate HBM Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HBM Holdings has a P/E ratio of 14.1x.
See valuation multiples for HBM Holdings and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $791M | XXX | $791M | XXX | XXX | XXX |
| EV (current) | $686M | XXX | $686M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 141.3x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 531.4x | XXX | XXX | XXX |
| EV/EBIT | 12.4x | XXX | -2463.6x | XXX | XXX | XXX |
| EV/Gross Profit | 6.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.1x | XXX | 2235.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 176.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHBM Holdings's last 12 month revenue growth is 29%
HBM Holdings's revenue per employee in the last FY averaged $27K, while opex per employee averaged $26K for the same period.
HBM Holdings's rule of 40 is 64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HBM Holdings's rule of X is 150% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for HBM Holdings and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 390% | XXX | XXX | XXX |
| EBITDA Margin | 77% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | 510% | XXX | XXX | XXX |
| Rule of 40 | 64% | XXX | 56% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 150% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $26K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 94% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HBM Holdings acquired XXX companies to date.
Last acquisition by HBM Holdings was XXXXXXXX, XXXXX XXXXX XXXXXX . HBM Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was HBM Holdings founded? | HBM Holdings was founded in 2016. |
| Where is HBM Holdings headquartered? | HBM Holdings is headquartered in Hong Kong. |
| How many employees does HBM Holdings have? | As of today, HBM Holdings has 177 employees. |
| Is HBM Holdings publicy listed? | Yes, HBM Holdings is a public company listed on HKG. |
| What is the stock symbol of HBM Holdings? | HBM Holdings trades under 02142 ticker. |
| When did HBM Holdings go public? | HBM Holdings went public in 2020. |
| Who are competitors of HBM Holdings? | Similar companies to HBM Holdings include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of HBM Holdings? | HBM Holdings's current market cap is $791M |
| What is the current revenue of HBM Holdings? | HBM Holdings's last 12 months revenue is $862M. |
| What is the current revenue growth of HBM Holdings? | HBM Holdings revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of HBM Holdings? | Current revenue multiple of HBM Holdings is 6.2x. |
| Is HBM Holdings profitable? | Yes, HBM Holdings is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of HBM Holdings? | HBM Holdings's last 12 months EBITDA is $662M. |
| What is HBM Holdings's EBITDA margin? | HBM Holdings's last 12 months EBITDA margin is 77%. |
| What is the current EV/EBITDA multiple of HBM Holdings? | Current EBITDA multiple of HBM Holdings is 8.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
